Irbesartan Accord

Irbesartan, the active ingredient in Irbesartan Accord, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure and to protect kidney function in patients with diabetes, and may be used in selected cases of heart failure.

GNH USA supplies Irbesartan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is available for bulk and unit‑dose distribution.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and related complications.

- Hypertension: reduces systolic and diastolic pressure, helping achieve target blood pressure levels. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure (off‑label): may improve symptoms and reduce hospitalisation when added to standard therapy.

Irbesartan may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Mild hyperkalemia

Serious or Rare Side Effects: - Angioedema - Severe hyperkalemia - Acute renal failure - Hepatic injury - Significant hypotension

When prescribing Irbesartan, clinicians should observe several safety considerations.

- Blood pressure monitoring: check for adequate control and avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before initiation and periodically. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy: avoid use during pregnancy due to risk of fetal toxicity. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and kidney injury. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - NSAIDs (high‑dose or chronic): can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium concentrations, requiring serum level monitoring. - Cyclosporine or tacrolimus: can raise drug levels, necessitating dose adjustment. - Rifampin: may reduce Irbesartan plasma concentrations, potentially lowering efficacy. - Thiazide diuretics: may enhance antihypertensive effect, watch for hypotension.